Your browser doesn't support javascript.
loading
The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.
Torrano, Veronica; Valcarcel-Jimenez, Lorea; Cortazar, Ana Rosa; Liu, Xiaojing; Urosevic, Jelena; Castillo-Martin, Mireia; Fernández-Ruiz, Sonia; Morciano, Giampaolo; Caro-Maldonado, Alfredo; Guiu, Marc; Zúñiga-García, Patricia; Graupera, Mariona; Bellmunt, Anna; Pandya, Pahini; Lorente, Mar; Martín-Martín, Natalia; Sutherland, James David; Sanchez-Mosquera, Pilar; Bozal-Basterra, Laura; Zabala-Letona, Amaia; Arruabarrena-Aristorena, Amaia; Berenguer, Antonio; Embade, Nieves; Ugalde-Olano, Aitziber; Lacasa-Viscasillas, Isabel; Loizaga-Iriarte, Ana; Unda-Urzaiz, Miguel; Schultz, Nikolaus; Aransay, Ana Maria; Sanz-Moreno, Victoria; Barrio, Rosa; Velasco, Guillermo; Pinton, Paolo; Cordon-Cardo, Carlos; Locasale, Jason W; Gomis, Roger R; Carracedo, Arkaitz.
Afiliação
  • Torrano V; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Valcarcel-Jimenez L; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Cortazar AR; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Liu X; Department of Pharmacology and Cancer Biology, Duke Cancer Institute, Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
  • Urosevic J; Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), The Barcelona Institute of Science and Technology, Barcelona 08028, Catalonia, Spain.
  • Castillo-Martin M; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Fernández-Ruiz S; Department of Pathology, Fundação Champalimaud, Lisboa, Portugal.
  • Morciano G; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Caro-Maldonado A; Dept. of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Italy.
  • Guiu M; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Zúñiga-García P; Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), The Barcelona Institute of Science and Technology, Barcelona 08028, Catalonia, Spain.
  • Graupera M; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Bellmunt A; Vascular Signalling Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Gran Via de l'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
  • Pandya P; Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), The Barcelona Institute of Science and Technology, Barcelona 08028, Catalonia, Spain.
  • Lorente M; Tumour Plasticity Team, Randall Division of Cell and Molecular Biophysics, King's College London, New Hunt's House, Guy's Campus, London SE1 1UL, UK.
  • Martín-Martín N; Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University and Instituto de Investigaciones Sanitarias San Carlos (IdISSC) 28040 Madrid, Spain.
  • Sutherland JD; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Sanchez-Mosquera P; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Bozal-Basterra L; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Zabala-Letona A; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Arruabarrena-Aristorena A; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Berenguer A; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Embade N; Biostatistics / Bioinformatics Unit, - IRB Barcelona, Parc Científic de Barcelona, 08028 Barcelona, Spain.
  • Ugalde-Olano A; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Lacasa-Viscasillas I; Department of Pathology, Basurto University Hospital, 48013 Bilbao, Spain.
  • Loizaga-Iriarte A; Department of Urology, Basurto University Hospital, 48013 Bilbao, Spain.
  • Unda-Urzaiz M; Department of Urology, Basurto University Hospital, 48013 Bilbao, Spain.
  • Schultz N; Department of Urology, Basurto University Hospital, 48013 Bilbao, Spain.
  • Aransay AM; Computational Biology, Memorial Sloan-Kettering Cancer Center, NY, 10065, USA.
  • Sanz-Moreno V; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Barrio R; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).
  • Velasco G; Tumour Plasticity Team, Randall Division of Cell and Molecular Biophysics, King's College London, New Hunt's House, Guy's Campus, London SE1 1UL, UK.
  • Pinton P; CIC bioGUNE, Bizkaia Technology Park, 801 bld., 48160 Derio, Bizkaia, Spain.
  • Cordon-Cardo C; Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University and Instituto de Investigaciones Sanitarias San Carlos (IdISSC) 28040 Madrid, Spain.
  • Locasale JW; Dept. of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Italy.
  • Gomis RR; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Carracedo A; Department of Pharmacology and Cancer Biology, Duke Cancer Institute, Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Nat Cell Biol ; 18(6): 645-656, 2016 06.
Article em En | MEDLINE | ID: mdl-27214280
ABSTRACT
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α-ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo / Mitocôndrias Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Nat Cell Biol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo / Mitocôndrias Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Nat Cell Biol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha